Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer’s disease. Their findings, based on studies in cell culture, mice and tissue samples from patients, may contribute to the development of more effective therapies. They are published in the scientific journal “Immunity”. 

The University Council of the University of Bonn has a new chairman: The committee unanimously elected the Secretary General of the Volkswagen Foundation, Dr. Georg Schütte, to succeed Prof. Dr. Dieter Engels, who had chaired the University Council since 2013.

Professor Simon Stellmer,  a member of the Cluster of Excellence ML4Q, receives a ‘Proof of Concept Grant’ from the European Research Council (ERC) for his project „GyroRevolutionPlus“. With the funding of €150,000 for up to 18 months, the physicist will continue to prepare his research results from previous ERC projects for commercial application. This is the second time that Professor Stellmer has been successful in this funding program after having received a grant for his previous project ‘GyroRevolution’ in 2023. The precision instruments he and his team are developing can be used to improve natural disaster early warning systems.

Around 1,500 schoolchildren from six EU countries have been engaged in intensive study of some of the challenges currently facing the world in the company of natural science experts. After completing each module on a different topic, they have been acting as “multipliers,” sharing their knowledge and experiences with their family, friends and classmates. Three schools from Bonn took part.

The “Bone2Gene” project of researchers from the University of Bonn and University Hospital Bonn has been awarded funding worth €1,000,000 as part of the Federal Ministry of Education and Research’s GO-Bio initial program. The money is now enabling the team to progress to the feasibility phase and get its product ready for market launch. This is actually the second grant that the project has secured, the first having been used for the conceptual phase and to test the product’s marketability. “Bone2Gene“ is using artificial intelligence (AI) to make genetic bone conditions known as skeletal dysplasia easier to spot and diagnose.

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now been able to show that local LLMs can help structure radiological findings in a privacy-safe manner, with all data remaining at the hospital. They compared various LLMs on public reports without data protection and on data-protected reports. Commercial models that require data transfer to external servers showed no advantage over local, data protection-compliant models. The results have now been published in the journal "Radiology".

AI applications like ChatGPT are based on artificial neural networks that, in many respects, imitate the nerve cells in our brains. They are trained with vast quantities of data on high-performance computers, gobbling up massive amounts of energy in the process. Spiking neurons, which are much less energy-intensive, could be one solution to this problem. In the past, however, the normal techniques used to train them only worked with significant limitations. A recent study by the University of Bonn has now presented a possible new answer to this dilemma, potentially paving the way for new AI methods that are much more energy-efficient. The findings have been published in Physical Review Letters.

Asthma, atopic dermatitis or Hashimoto's thyroiditis as concomitant diseases are risk factors for clinical features associated with a poor prognosis in circular hair loss, also known as alopecia areata (AA). In patients with three atopic diseases, namely atopic dermatitis, asthma and rhinitis, the average age of onset of AA is about ten years earlier than in patients without chronic inflammatory comorbidities. This has now been established by researchers from the University Hospital Bonn (UKB) and the University of Bonn in a large cohort study of affected patients. Their results have now been published in the journal "Allergy".